youtube_live
Q3 2026 earnings • in 2 days
See detailschevron_right
HALO:NASDAQ
Halozyme Therapeutics, Inc.
$128.95
0.00%
(0.00) 1D
$129.25
arrow_upward
+0.23% (+0.30)todayPre-market
Closed: Nov 2, 4:00:02 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Mkt. cap
14.64B
Avg. vol.
2.37M
Volume
418.00
P/E ratio
38.53
52-wk high
$134.00
52-wk low
$61.23
EPS
$3.35
Beta
0.92
Shares outstanding
113.50M
No. of employees
423
Mkt. cap
14.64B
Avg. vol.
2.37M
Volume
418.00
P/E ratio
38.53
52-wk high
$134.00
52-wk low
$61.23
EPS
$3.35
Beta
0.92
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
FinancialContent
·
1 hour ago
Chegg’s (NYSE:CHGG) Q3 2026: beats on revenue but quarterly revenue guidance slightly misses expectations
PR Newswire Canada
·
24 minutes ago
NYSE-Affiliated Venue for Tokenization Adds Transfer Agents: NYSE Content Update
Barchart.com
·
1 hour ago
Upstart (NASDAQ:UPST) posts better-than-expected sales in Q3 2026, stock soars
Seeking Alpha
·
32 minutes ago
It's Time To Go All-In On Stocks (SP500)
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com